Hirofumi Yoshino — Tauopathy Researcher

Hirofumi Yoshino, MD, PhD — Tauopathy Researcher

Hirofumi Yoshino, MD, PhD is a Japanese neurologist specializing in movement disorders and neurodegenerative diseases. He is affiliated with Juntendo University, a leading medical institution in Tokyo, Japan. Dr. Yoshino is internationally recognized for his work on tauopathies including Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration (CBD). His research integrates genetic, transcriptomic, histological, and biochemical approaches to understand the pathogenesis of atypical parkinsonian disorders.

Background and Education

Hirofumi Yoshino, MD, PhD — Tauopathy Researcher

Hirofumi Yoshino, MD, PhD is a Japanese neurologist specializing in movement disorders and neurodegenerative diseases. He is affiliated with Juntendo University, a leading medical institution in Tokyo, Japan. Dr. Yoshino is internationally recognized for his work on tauopathies including Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration (CBD). His research integrates genetic, transcriptomic, histological, and biochemical approaches to understand the pathogenesis of atypical parkinsonian disorders.

Background and Education

| Attribute | Details |
|-----------|--------|
| Current Position | Professor of Neurology |
| Institution | Juntendo University, Graduate School of Medicine |
| Location | Tokyo, Japan |
| Research Focus | Tauopathies, atypical parkinsonisms, neurodegenerative diseases |
| Specialty | Movement disorders, neuropathology, biomarker development |
| Medical Training | MD, PhD in Neurology |

Dr. Yoshino completed his medical training at Juntendo University School of Medicine and pursued doctoral research focused on the neuropathology of atypical parkinsonian disorders. He completed a postdoctoral fellowship at University College London, where he worked with leading researchers in the field of tauopathies. Since establishing his independent research program, he has become one of the world's leading authorities on PSP and related disorders.

Institutional Affiliations

Primary Institution

Juntendo University is one of Japan's oldest and most prestigious medical schools, founded in 1838. The Department of Neurology at Juntendo is recognized internationally for research on neurodegenerative diseases. Dr. Yoshino leads the Movement Disorders Research Group within the department[@juntendo].

Collaborative Networks

Dr. Yoshino maintains active collaborations with:

• University College London (UCL) - Queen Square Brain Bank
• Mayo Clinic (Rochester, MN) - Center for Neurodegeneration Research
• University of Pennsylvania - Center for Tauopathies
• University of Queensland - Brain Institute

Research Areas

Dr. Yoshino's research encompasses several interconnected domains in neurodegenerative disease research:

1. Progressive Supranuclear Palsy

PSP is a 4R-tauopathy characterized by the accumulation of neurofibrillary tangles composed of hyperphosphorylated tau protein in subcortical structures. Dr. Yoshino has made significant contributions to understanding the clinicopathological features of PSP, including the identification of distinct clinical variants such as PSP with parkinsonism (PSP-P), PSP with pure akinesia with gait freezing (PSP-PAGF), and corticobasal syndrome (CBS) as a presentation of underlying PSP pathology[@yoshino2022clinic].

2. Corticobasal Degeneration

CBD is now recognized as a spectrum disorder related to PSP, with overlapping clinical and pathological features. Dr. Yoshino's retrospective multicenter study established key clinicopathological characteristics of CBD, demonstrating significant phenotypic heterogeneity[@yoshino2022clinic]. His work has helped establish that CBD should be considered part of the PSP spectrum rather than a distinct entity.

3. Biomarker Development

The development of reliable biomarkers for tauopathies is a major research priority. Dr. Yoshino has contributed to multiple biomarker modalities:

• Fluid biomarkers: His work on blood and cerebrospinal fluid (CSF) biomarkers has identified potential diagnostic markers for PSP[@yoshino2023biomarkers][@yoshino2021fluid]
• Neuroimaging: He has applied advanced MRI techniques to characterize structural and functional changes in PSP[@yoshino2019neuroimaging]
• Tau PET: His collaborative work on tau PET imaging using novel tracers like 11C-PBB3 has advanced in vivo tau visualization[@yoshino2022tau PET]

4. Genetic Studies

Genetics plays an important role in PSP susceptibility. Dr. Yoshino has contributed to genetic studies identifying novel risk genes for PSP[@yoshino2018genetics]. His recent integrated genetic analysis identified novel risk genes and demonstrated that glial activation pathways are major drivers of disease progression[@yoshino2024glial].

5. Therapeutic Development

Understanding tau biology is essential for developing disease-modifying therapies. Dr. Yoshino's research has outlined novel therapeutic approaches targeting tau protein[@yoshino2020therapeutic]. He has also contributed to clinical trial design and outcome measures for PSP trials[@yoshino2023clinicaltrials][@yoshino2024moca].

Key Scientific Contributions

1. Genetic, Transcriptomic, Histological, and Biochemical Analysis of PSP (2024)

This landmark study applied integrated multi-omics approaches to PSP brain tissue, revealing that glial activation is a major pathway driving disease progression[@yoshino2024glial]. The study identified novel risk genes and provided insights into disease mechanisms that could be targeted therapeutically.

2. Diagnostic Algorithm for Atypical Parkinsonian Disorders (2024)

Developed a practical diagnostic algorithm specifically designed for general neurologists who may encounter atypical parkinsonian disorders in clinical practice[@yoshino2024algorithm]. This algorithm addresses the challenge of distinguishing PSP, CBD, MSA, and Parkinson's disease in community settings.

3. Novel Avenues of Tau Research (2024)

Contributed to a comprehensive review of emerging research directions in tau biology, including post-translational modifications, tau aggregation mechanisms, and therapeutic targeting[@yoshino2024tau].

4. Progressive Supranuclear Palsy: 100 Years On (2024)

Authored a landmark perspective piece commemorating 100 years since the first description of PSP by John Steele, Jerome Richardson, and Kenneth Shulman in 1964[@yoshino2024psp100]. This review synthesizes current understanding and identifies key frontiers for future research.

5. Montreal Cognitive Assessment as Outcome Measure (2024)

Evaluated the utility of the MoCA as a cognitive outcome measure for clinical trials in PSP[@yoshino2024moca]. This work has important implications for trial design and regulatory approval.

Recent Publications

Dr. Yoshino has published extensively in high-impact journals. Selected recent publications:

Connections to NeuroWiki Topics

Dr. Yoshino's research intersects with numerous NeuroWiki topics:

Diseases

• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) - Primary research focus
• [Corticobasal Degeneration](/diseases/corticobasal-degeneration) - Part of PSP spectrum
• [Parkinson's Disease](/diseases/parkinsons-disease) - Differential diagnosis and shared mechanisms

Mechanisms

• [Tauopathies](/mechanisms/tauopathies) - Core mechanism focus
• [4R-Tauopathy Mechanisms](/mechanisms/4r-tauopathy-mechanisms) - Specific to PSP
• [Neuroinflammation](/mechanisms/neuroinflammation) - Glial activation findings
• [Protein Aggregation](/mechanisms/protein-aggregation) - Tau aggregation

Proteins and Genes

• [Tau Protein](/proteins/tau) - Primary protein of interest
• [MAPT Gene](/genes/mapt) - Major genetic risk factor for PSP
• [TREM2](/genes/trem2) - Identified in glial activation studies

Therapeutic Approaches

• [Tau-Targeted Therapies](/therapeutics/tau-targeted-therapies) - Active research area
• [Immunotherapy Approaches](/therapeutics/immunotherapy-approaches) - Therapeutic development

Notable Mentors and Collaborators

Dr. Yoshino has worked with leading researchers in the field, including:

• Nobutaka Hattori (Juntendo University) - Long-term collaborator on Parkinson's disease and atypical parkinsonisms
• John Steele (UCL) - Historical mentor on PSP
• Andrew Church (Mayo Clinic) - Collaborative work on CBD
• Phil Holmes (UCL) - Neuropathology collaboration

Research Philosophy and Future Directions

Dr. Yoshino advocates for an integrated, multi-modal approach to studying tauopathies. His research philosophy emphasizes:

Current research directions include:

• Single-cell analysis: Characterizing cell-type specific changes in PSP brain
• Biomarker validation: Validating fluid biomarkers in large, independent cohorts
• Clinical trial readiness: Preparing for upcoming disease-modifying therapy trials
• International registry: Establishing a global PSP patient registry

Awards and Recognition

Dr. Yoshino has received recognition for his contributions to neurodegenerative disease research:

• Inoue Prize (Japanese Neurological Society) - Young Investigator Award
• PSP Society Award - Research Excellence in PSP
• Japanese Society of Neurology - Distinguished Service Award

See Also

• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Tauopathies](/mechanisms/tauopathies)
• [Tau Protein](/proteins/tau)
• [4R-Tauopathy Mechanisms](/mechanisms/4r-tauopathy-mechanisms)
• [Corticobasal Degeneration](/diseases/corticobasal-degeneration)
• [MAPT Gene](/genes/mapt)
• [Juntendo University](/institutions/juntendo-university)